The Molecular Cytogenetics Core provides valuable scientific and technical support to MSK investigators exploring the role of chromosomal instability in cancer. This is accomplished through appropriate and efficient experiment design, custom multi-color DNA-FISH probe design and development, data analysis and interpretation, and support with manuscript/grant preparation. Currently, the Core provides 2 main categories of specialized service that operate at the single-cell level on a variety of human and animal model research samples: conventional karyotyping and fluorescence in situ hybridization (FISH). Conventional karyotyping is routinely performed to confirm cell line identity, screen targeted mouse ESC clones intended for blastocyst injection, monitor the stability of cultured stem cells over time, and measure chromosomal instability/heterogeneity as an experimental endpoint. Over the years, the Core has assembled a broad range of molecular cytogenetics resources (plasmids, BAC clones, individual whole chromosome painting probes), allowing the Core to provide FISH services at significantly lower cost. FISH-based assays are routinely employed to map genes or transgene integration sites, detect aneuploidy/chromosomal instability, co-detect DNA/protein and assess intra-tumoral heterogeneity; tests include custom probe development, locus-specific FISH, whole-chromosome painting (WCP), spectral karyotyping (SKY), Q-FISH, and Immuno-FISH. The Core is equipped with 5 modern Fluorescence imaging systems including 2 with a wide range of applications that can be fully or partially automated. The Core also provides training in tissue culture, karyotyping, and FISH. During the past grant period, the services and collaborative work provided by the Molecular Cytogenetics Core have supported the research of 84 investigators from 8 research program.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA008748-55
Application #
10084813
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
1997-01-20
Project End
2023-12-31
Budget Start
2021-01-01
Budget End
2021-12-31
Support Year
55
Fiscal Year
2021
Total Cost
Indirect Cost
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Hsin, Jing-Ping; Lu, Yuheng; Loeb, Gabriel B et al. (2018) The effect of cellular context on miR-155-mediated gene regulation in four major immune cell types. Nat Immunol 19:1137-1145
Senders, Max L; Hernot, Sophie; Carlucci, Giuseppe et al. (2018) Nanobody-Facilitated Multiparametric PET/MRI Phenotyping of Atherosclerosis. JACC Cardiovasc Imaging :
Rogers, Emma M; Connolly, Karen L; Nehal, Kishwer S et al. (2018) Comorbidity scores associated with limited life expectancy in the very elderly with nonmelanoma skin cancer. J Am Acad Dermatol 78:1119-1124
Flinn, Ian W; O'Brien, Susan; Kahl, Brad et al. (2018) Duvelisib, a novel oral dual inhibitor of PI3K-?,?, is clinically active in advanced hematologic malignancies. Blood 131:877-887
Gay, Hiram A; Oh, Jung Hun; Apte, Aditya P et al. (2018) Predictors of acute throat or esophageal patient reported pain during radiation therapy for head and neck cancer. Clin Transl Radiat Oncol 13:1-6
Touijer, Karim A; Karnes, Robert Jeffery; Passoni, Niccolo et al. (2018) Survival Outcomes of Men with Lymph Node-positive Prostate Cancer After Radical Prostatectomy: A Comparative Analysis of Different Postoperative Management Strategies. Eur Urol 73:890-896
Pianko, Matthew J; Moskowitz, Alison J; Lesokhin, Alexander M (2018) Immunotherapy of Lymphoma and Myeloma: Facts and Hopes. Clin Cancer Res 24:1002-1010
Bucciarelli, Peter R; Tan, Kay See; Chudgar, Neel P et al. (2018) BRMS1 Expression in Surgically Resected Lung Adenocarcinoma Predicts Future Metastases and Is Associated with a Poor Prognosis. J Thorac Oncol 13:73-84
Yang, Annie; Baxi, Shrujal; Korenstein, Deborah (2018) ClinicalTrials.gov for Facilitating Rapid Understanding of Potential Harms of New Drugs: The Case of Checkpoint Inhibitors. J Oncol Pract 14:72-76
Mikropoulos, Christos; Selkirk, Christina G Hutten; Saya, Sibel et al. (2018) Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predisposition. Br J Cancer 118:266-276

Showing the most recent 10 out of 8799 publications